Kronos Bio saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Kronos Bio‘s patent filings and grants. Buy the databook here.
Kronos Bio has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 50% of filings. The World Intellectual Property Organization(WIPO), Australia(AU), and United States(US) patent Office are among the top ten patent offices where Kronos Bio is filings its patents..
Gilead Sciences and Roche could be the strongest competitors for Kronos Bio
Patents related to rare diseases lead Kronos Bio's portfolio
Kronos Bio has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Kronos Bio portfolio followed by leukemia, and liver cancer
Kronos Bio has highest number of patents in breast cancer followed by leukemia, liver cancer, advanced malignancy, and acute lymphocytic leukemia (all, acute lymphoblastic leukemia).
For comprehensive analysis of Kronos Bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.